Aggravation of coronary heart disease: the balance of risk and the risk of disease treatment

Cover Page

Cite item

Full Text

Abstract

This review describes current approaches to the treatment of patients who have had an episode of acute ischemic heart disease. Summarizes studies of oral direct inhibitors of hemostasis in this pathology. The only drug of this group rivaroxaban, despite a slight increase in the frequency of bleeding, has demonstrated efficacy in reducing total mortality in thesepatients. Particular attention is given today interventional procedures, which may also serve as a source of additional problems, especially stent thrombosis. Rivaroxaban has proved effective in reducing the frequency of this complication.

About the authors

V. A Braznik

Healthcare City clinical hospital №51 of Moscow Healthcare department

канд. мед. наук, главный врач ГБУЗ ГКБ №51 121309, Russian Federation, Moscow, ul. Alabieva, d. 7/33

D. A Zateyshchikov

Healthcare City clinical hospital №51 of Moscow Healthcare department

Email: dz@bk.ru
д-р мед. наук, проф., рук. первичного сосудистого отделения ГБУЗ ГКБ №51 121309, Russian Federation, Moscow, ul. Alabieva, d. 7/33

References

  1. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998, 338 (21): 1498-505.
  2. Cannon C.P, Mc Cabe C.H, Wilcox R.G et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102 (2): 149-56.
  3. Mahaffey K.W, Wojdyla D.M, Carroll K et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124 (5): 544-54.
  4. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347 (13): 969-74.
  5. Wallentin L, Wilcox R.G, Weaver W.D et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362 (9386): 789-97.
  6. Oldgren J, Budaj A, Granger C.B et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double - blind, phase II trial. Eur Heart J 2011; 32 (22): 2781-9.
  7. Douxfils J, Buckinx F, Mullier F et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all - cause mortality: a systematic review and meta - analysis of randomized controlled trials. J Am Heart Assoc 2014, 3 (3): e000515.
  8. Alexander J.H, Becker R.C, Bhatt D.L et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAI- SE) trial. Circulation 2009; 119 (22): 2877-85.
  9. Alexander J.H, Lopes R.D, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365 (8): 699-708.
  10. Hess C.N, James S, Wojdyla D.M et al. Apixaban Plus Mono versus Dual Antiplatelet Therapy After Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial. Circulation 2014; 130 (Suppl. 2): A14643.
  11. Loke Y.K, Pradhan S, Yeong J.K, Kwok C.S. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta - analysis and adjusted indirect comparison. Br J Clin Pharmacol 2014; 78 (4): 707-17.
  12. Mega J.L, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double - blind, phase II trial. Lancet 2009; 374 (9683): 29-38.
  13. Mega J.L, Braunwald E, Wiviott S.D et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012; 366 (1): 9-19.
  14. Mauri L, Kereiakes D.J, Yeh R.W et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014; 371 (23): 2155-66.
  15. Reejhsinghani R, Lotfi A.S. Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag 2015; 11: 93-106.
  16. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug - eluting stents. J Am Med Assoc 2005; 293 (17): 2126-30.
  17. Kohn C.G, Kluger J, Azeem M, Coleman C.I. Short - term consequences of angiographically - confirmed coronary stent thrombosis. PLoS One 2013; 8 (10): e77330.
  18. Cutlip D.E, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115 (17): 2344-51.
  19. Yadav M, Genereux P., Palmerini T et al. SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST- segment elevation acute coronary syndromes: an ACUITY trial substudy. Catheter Cardiovascular Interv 2015; 85 (1): 1-10.
  20. Finn A.V, Joner M, Nakazawa G et al. Pathological correlates of late drug - eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115 (18): 2435-41.
  21. Otsuka F, Nakano M, Ladich E et al. Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. Thrombosis 2012; 2012: 608593.
  22. Van Werkum J.W, Heestermans A.A, Zomer A.C et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53 (16): 1399-409.
  23. Claessen B.E, Henriques J.P, Jaffer F.A et al. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv 2014; 7 (10): 1081-92.
  24. Dangas G.D, Claessen B.E, Mehran R et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv 2012; 5 (11): 1097-105.
  25. Steg P.G, Harrington R.A, Emanuelsson H et al for the P.S.G.Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial. Circulation 2013; 128 (10): 1055-65.
  26. Gibson C.M, Chakrabarti A.K, Mega J et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 2013; 62 (4): 286-90.
  27. Dewilde W.J, Oirbans T, Verheugt F.W et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open - label, randomised, controlled trial. Lancet 2013; 381 (9872): 1107-15.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies